Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445082 | 0.88 | DPP4 (0.74) | DPP4DPP9KLK5 | |
| SCHEMBL5445079 | 0.88 | DPP4 (0.74) | DPP4DPP9KLK5 | |
| Hydrochloric Acid SCHEMBL5447320 | 0.86 | DPP4 (0.76) | DPP4DPP9DPP8 | |
| SCHEMBL5456386 | 0.83 | DPP4 (0.46) | DPP4DPP9NPSR1NPC1L3MBTL1 | |
| SCHEMBL5456032 | 0.83 | DPP4 (0.46) | DPP4LMNANPC1L3MBTL1ALDH1A1 | |
| SCHEMBL5456427 | 0.83 | DPP4 (0.42) | DPP4DPP9DPP8 | |
| SCHEMBL5449696 | 0.82 | DPP4 (0.48) | DPP4DPP9DPP8 | |
| SCHEMBL5740676 | 0.81 | DPP4 (0.41) | DPP4DPP9NPC1DPP8ALDH1A1 | |
| SCHEMBL27643640 | 0.81 | DPP4 (0.70) | DPP4DPP9KLK5 | |
| SCHEMBL5451704 | 0.78 | DPP4 (0.47) | DPP4DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | DPP4 1/4885DPP9 5/4885KLK5 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.